Mission

To develop precision medicines that target hypoxic (low oxygen) areas in tumours that conventional chemotherapy, immunotherapy and radiotherapy do not treat. Hypoxia is recognized as a key resistance factor affecting all cancer treatments

uHAPs: a tumour agnostic therapy 2 lead assets, at different phases of development

  • 2 lead assets, at different phases of development
  • uHAP 1: extensive Phase I experience, excellent safety profile
  • uHAP 2: second generation molecule - broad applications in many tumours

The uHAP Competitive Advantage

Non-Cytotoxic Prodrugs

minimal effects compared to conventional cytotoxics

Excellent Penetration

across all tissues, crosses the blood brain barrier

Irreversible

effective, persistent TOPO 2 Inhibitors at target hypoxic sites

ASSET INDICATION / ROUTE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III
uHAP 1 Pancreatic ductal adenocarcinoma (PDAC) (2nd line add-on therapy) / ORPHAN       Phase II ready  
Glioblastoma multiforme (GBM) (add-on to Temozolamide + RT) / ORPHAN       Phase II ready  
Diffuse Intrinsic Pontine Glioma (DIPG) (add-on to RT) / ORPHAN       Phase II ready  
uHAP 2 Prostate Cancer Focus Broad range of Cancers / PATENTED THERAPY   Pre-clinical ready

Contact

OncoTherics Poland Spółka Akcyjna
ul. prof. Michała Bobrzyńskiego 14
30-348 Kraków
Poland

Copyright © 2010 - 2020 All rights reserved